Comparing the effects of different sodium-glucose link transporter 2 inhibitors (SGLT2i) on HbA1c and weight in the real world: Updated analysis from the Association of British Clinical Diabetologists (ABCD) audit programmes

被引:0
|
作者
Crabtree, T. S. J. [1 ,2 ,3 ]
Dhatariya, K. [4 ]
Bickerton, A. [5 ]
Sivappriyan, S. [6 ]
Barnes, D. [6 ]
Tarpey, S. [7 ]
Rowles, S. [7 ]
Adamson, K. [8 ]
Gallen, I. [9 ]
Ryder, R. E. J. [1 ]
机构
[1] Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Dept Diabet & Endocrinol, Birmingham, W Midlands, England
[2] Univ Hosp Derby & Burton NHS Trust, Royal Derby Hosp, Dept Diabet & Endocrinol, Derby, England
[3] Univ Nottingham, Royal Derby Hosp, Sch Med, Derby, England
[4] Norfolk & Norwich Univ Hosp NHS Trust, Dept Diabet & Endocrinol, Norwich, Norfolk, England
[5] Yeovil Dist Hosp NHS FT, Dept Diabet & Endocrinol, Yeovil, England
[6] Maidstone & Tunbridge Wells Hosp NHS Trust, Dept Diabet, Maidstone, Kent, England
[7] Pennine Acute Hosp NHS Trust, Dept Diabet & Endocrinol, Manchester, Lancs, England
[8] St Johns Hosp, Dept Diabet & Endocrinol, Livingston, Scotland
[9] Royal Berkshire Hosp NHS Trust, Dept Diabet, Reading, Berks, England
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A20 (P245)
引用
收藏
页数:3
相关论文
共 24 条
  • [21] COMBINED THERAPY WITH SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA)-TOLERABILITY AND CLINICAL IMPACT: THE INTERMOUNTAIN HEALTHCARE REAL WORLD EXPERIENCE
    Le, Viet T.
    Perez-Moreno, Ana Cristina
    Calderone, Peter
    Epstein, Josh
    Muhlestein, J. Brent
    Knowlton, Kirk U.
    Anderson, Jeffrey L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1443 - 1443
  • [22] What effect do sodium-glucose co-transporter-2 (SGLT2) inhibitors have on heart failure in real-world clinical practice? A meta-analysis of observational studies
    Hinton, W.
    Ansari, A. S.
    Whyte, M. B.
    McGovern, A. P.
    Feher, M. D.
    Munro, N.
    de Lusignan, S.
    DIABETIC MEDICINE, 2021, 38
  • [23] Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis
    Seufert, Jochen
    Lanzinger, Stefanie
    Danne, Thomas
    Bramlage, Peter
    Schmid, Sebastian M.
    Kopp, Florian
    Kress, Stephan
    Fasching, Peter
    Schaefer, Claus
    Holl, Reinhard W.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 742 - 746
  • [24] Comparative Efficacy of Ertugliflozin (ERTU) plus Sitagliptin (SITA) vs. Other Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) + Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Combinations: Model-Based Meta-analysis (MBMA) of HbA1c Lowering
    Fediuk, Daryl
    Mandema, Jaap
    Sweeney, Kevin
    Terra, Steven G.
    Sahasrabudhe, Vaishali
    DIABETES, 2019, 68